Sök i LIBRIS databas

  Utökad sökning


Sökning: onr:"swepub:oai:DiVA.org:uu-303024" > Fracture Rate, Qual...

Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide : 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

Langdahl, Bente L. (författare)
Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Tage Hansens Gade 2, DK-8000 Aarhus, Denmark.
Ljunggren, Östen (författare)
Uppsala universitet,Endokrinologi och mineralmetabolism
Benhamou, Claude-Laurent (författare)
Orleans Hosp, Orleans, France.
visa fler...
Marin, Fernando (författare)
Eli Lilly & Co, Windlesham, Surrey, England.
Kapetanos, George (författare)
Papageorgiou Gen Hosp, Thessaloniki, Greece.
Kocjan, Tomaz (författare)
Univ Med Ctr, Ljubljana, Slovenia.
Lespessailles, Eric (författare)
Orleans Hosp, Orleans, France.;Univ Orleans, EA 4708 I3MTO, Orleans, France.
Napoli, Nicola (författare)
Univ Campus Biomed, Rome, Italy.
Nikolic, Tatjana (författare)
Univ Hosp, Zagreb, Croatia.
Petto, Helmut (författare)
Eli Lilly & Co, Windlesham, Surrey, England.
Moll, Thomas (författare)
Eli Lilly & Co, Windlesham, Surrey, England.
Lindh, Erik (författare)
Eli Lilly & Co, Windlesham, Surrey, England.
visa färre...
Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Tage Hansens Gade 2, DK-8000 Aarhus, Denmark Endokrinologi och mineralmetabolism (creator_code:org_t)
Ingår i: Calcified Tissue International. - 0171-967X .- 1432-0827. ; 99:3, s. 259-271
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
  • We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(A (R)) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study. Data on incident clinical fractures, HRQoL (EQ-5D questionnaire) and back pain [100 mm visual analogue scale (VAS)] were collected. The number of patients with fractures was summarised in 6-month intervals and fracture rate over each 6-month period was assessed using logistic regression for repeated measures. Changes from baseline in EQ-5D and back pain VAS were analysed using mixed models for repeated measures. Of 1454 patients in the active treatment cohort, 90.6 % were female and 14.4 % were taking glucocorticoids. During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral). A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the > 18- to 24-month period versus the first 6-month period (both p < 0.05). EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment. In conclusion, patients with severe osteoporosis showed a significant reduction in the incident fracture rate during 24 months of teriparatide treatment in routine clinical practice, accompanied by a significant improvement in HRQoL and reduction in back pain. Results should be interpreted in the context of the non-controlled design of this observational study.


MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)


Observational study
Quality of life
Back pain

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy